These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 20461469

  • 21. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S.
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [Abstract] [Full Text] [Related]

  • 22. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
    Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L.
    J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
    [Abstract] [Full Text] [Related]

  • 23. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
    Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ.
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
    [Abstract] [Full Text] [Related]

  • 24. [Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
    Orcajo Rincón J, Alonso Farto JC, Rotger Regi A, Hernández Pérez R, Hualde AM, Pérez Aradas V.
    Rev Esp Med Nucl; 2011 May; 30(5):307-10. PubMed ID: 21641092
    [Abstract] [Full Text] [Related]

  • 25. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
    Bille A, Chicklore S, Okiror L, Cook GJ, Spicer J, Landau D, Lang-Lazdunski L.
    Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
    [Abstract] [Full Text] [Related]

  • 26. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
    Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR.
    Radiographics; 2004 Nov; 24(1):105-19. PubMed ID: 14730040
    [Abstract] [Full Text] [Related]

  • 27. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ.
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [Abstract] [Full Text] [Related]

  • 28. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
    Basu S, Saboury B, Torigian DA, Alavi A.
    Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
    [Abstract] [Full Text] [Related]

  • 29. Current trends in radiologic management of malignant pleural mesothelioma.
    Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H.
    Semin Thorac Cardiovasc Surg; 2009 Oct; 21(2):111-20. PubMed ID: 19822282
    [Abstract] [Full Text] [Related]

  • 30. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
    Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S.
    Cancer Biother Radiopharm; 2004 Apr; 19(2):149-54. PubMed ID: 15186594
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW.
    PLoS One; 2020 Apr; 15(2):e0229299. PubMed ID: 32069313
    [Abstract] [Full Text] [Related]

  • 32. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR.
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [Abstract] [Full Text] [Related]

  • 33. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
    Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ.
    Clin Cancer Res; 2010 Apr 15; 16(8):2409-17. PubMed ID: 20371686
    [Abstract] [Full Text] [Related]

  • 34. FDG PET/CT in the management of primary pleural tumors and pleural metastases.
    Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM.
    AJR Am J Roentgenol; 2013 Aug 15; 201(2):W215-26. PubMed ID: 23883236
    [Abstract] [Full Text] [Related]

  • 35. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
    Mineo TC, Ambrogi V, Cufari ME, Pompeo E.
    Eur J Cardiothorac Surg; 2010 Sep 15; 38(3):245-52. PubMed ID: 20338775
    [Abstract] [Full Text] [Related]

  • 36. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
    Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A.
    Chest; 1998 Sep 15; 114(3):713-22. PubMed ID: 9743156
    [Abstract] [Full Text] [Related]

  • 37. 18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
    Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G.
    Hell J Nucl Med; 2018 Sep 15; 21(3):191-197. PubMed ID: 30411729
    [Abstract] [Full Text] [Related]

  • 38. 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
    Niccoli-Asabella A, Notaristefano A, Rubini D, Altini C, Ferrari C, Merenda N, Fanelli M, Rubini G.
    Clin Imaging; 2013 Sep 15; 37(6):1098-103. PubMed ID: 23932389
    [Abstract] [Full Text] [Related]

  • 39. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
    Liu F, Zhao B, Krug LM, Ishill NM, Lim RC, Guo P, Gorski M, Flores R, Moskowitz CS, Rusch VW, Schwartz LH.
    J Thorac Oncol; 2010 Jun 15; 5(6):879-84. PubMed ID: 20421814
    [Abstract] [Full Text] [Related]

  • 40. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
    Truong MT, Marom EM, Erasmus JJ.
    J Thorac Imaging; 2006 May 15; 21(2):146-53. PubMed ID: 16770231
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.